Exodus Point Capital Management, LP Allogene Therapeutics, Inc. Transaction History
Exodus Point Capital Management, LP
- $13.1 Billion
- Q1 2024
A detailed history of Exodus Point Capital Management, LP transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 163,023 shares of ALLO stock, worth $389,624. This represents 0.01% of its overall portfolio holdings.
Number of Shares
163,023
Previous 109,990
48.22%
Holding current value
$389,624
Previous $349,000
108.88%
% of portfolio
0.01%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ALLO
# of Institutions
162Shares Held
106MCall Options Held
97.5KPut Options Held
45.6K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$44.7 Million1.76% of portfolio
-
Black Rock Inc. New York, NY9.65MShares$23.1 Million0.0% of portfolio
-
State Street Corp Boston, MA9.18MShares$21.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.21MShares$19.6 Million0.0% of portfolio
-
Primecap Management CO Pasadena, CA5.45MShares$13 Million0.02% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $344M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...